Replies to post #356692 on Elite Pharmaceuticals Inc (ELTP)

[DSherman]

Exactly, good post!!
Eltp $$$$$$$

[dr_lowenstein]

notice that the firm is never identified, no details ever disclosed about the methods and assumptions made= phony valuation

[jgsnys]

Once upon a time there was a CEO who was hired to grow a small pharmaceutical company. The CEO had been credited with a number of accomplishments, and it seemed quite possible that he could indeed make the small company a success. Having assumed the helm of the company, the CEO rested. . . on his um laurels. He farmed out tasks that would require real exertion from himself and everyone else at the company. What innovation he did bring to the company was severely misguided, resulting in a major-setback. Years passed. A mix of complacent nonchalance and ineptitude resulted in prior valuations for the company - from $0.40 to $2.75- which once seemed perhaps attainable, having to be regarded as fairy-dust.

[NASDAQ2020]

Excellent DD

[no2koolaid]

I trust we all know the reason that the valuation in 2013 was real…the valuation HAD to have been done to establish the poison pill. Elite simply could not have created the poison pill without a valuation, that is a fact. By the way, the poison pill is mentioned in the 2020 Annual Report, for those interested. The reason for the inclusion of the poison pill discussion in the 2020 Annual Report was to make sure it was clear that neither Nasrat nor LPC could engage in a hostile takeover of Elite – as was erroneously inferred. The poison pill was also identified in the 2014 Annual Report.

As to the three points ($0.40, $2.10 and $2.75) of value identified by the 2013 valuation analysis - clearly, they no longer apply as the basis for valuing what is now a profitable company would require a new valuation analysis in the event of Elite uplisting, being acquired or merging with another firm…or creating a new poison pill when the current one expires in November 2023. Such a valuation would recognize that Elite has significantly greater total assets now than in 2013, even in the face of an increased O/S.

[Je3232]

Different time based on different portfolio of drugs. Even then we never saw that price.